- Home
- AFRM vs ILMN Comparison
AFRM vs ILMN Comparison
Compare AFRM & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AFRM
- ILMN
- Stock Information
- Founded
- AFRM 2012
- ILMN 1998
- Country
- AFRM United States
- ILMN United States
- Employees
- AFRM N/A
- ILMN N/A
- Industry
- AFRM Business Services
- ILMN Medical Specialities
- Sector
- AFRM Consumer Discretionary
- ILMN Health Care
- Exchange
- AFRM Nasdaq
- ILMN Nasdaq
- Market Cap
- AFRM 16.1B
- ILMN 15.9B
- IPO Year
- AFRM 2021
- ILMN 2000
- Fundamental
- Price
- AFRM $51.90
- ILMN $82.24
- Analyst Decision
- AFRM Buy
- ILMN Buy
- Analyst Count
- AFRM 21
- ILMN 18
- Target Price
- AFRM $65.44
- ILMN $127.78
- AVG Volume (30 Days)
- AFRM 9.1M
- ILMN 2.4M
- Earning Date
- AFRM 05-08-2025
- ILMN 05-08-2025
- Dividend Yield
- AFRM N/A
- ILMN 3.78%
- EPS Growth
- AFRM N/A
- ILMN N/A
- EPS
- AFRM N/A
- ILMN N/A
- Revenue
- AFRM $3,007,180,000.00
- ILMN $4,337,000,000.00
- Revenue This Year
- AFRM $39.22
- ILMN N/A
- Revenue Next Year
- AFRM $23.19
- ILMN $3.22
- P/E Ratio
- AFRM N/A
- ILMN N/A
- Revenue Growth
- AFRM 42.55
- ILMN N/A
- 52 Week Low
- AFRM $22.25
- ILMN $68.70
- 52 Week High
- AFRM $82.53
- ILMN $156.66
- Technical
- Relative Strength Index (RSI)
- AFRM 53.66
- ILMN 53.42
- Support Level
- AFRM $46.71
- ILMN $78.55
- Resistance Level
- AFRM $53.35
- ILMN $85.90
- Average True Range (ATR)
- AFRM 2.54
- ILMN 2.92
- MACD
- AFRM -0.13
- ILMN 0.38
- Stochastic Oscillator
- AFRM 45.43
- ILMN 56.43
About AFRM Affirm Holdings Inc.
Affirm Holdings Inc offers a platform for digital and mobile-first commerce. It comprises a point-of-sale payment solution for consumers, merchant commerce solutions, and a consumer-focused app. The firm generates its revenue from merchant networks, and through virtual card networks among others. Geographically, it generates a majority share of its revenue from the United States.
About ILMN Illumina Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2023 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.